Discover BPC-157 dosage trends, reconstitution volumes, and vial size patterns aggregated from thousands of anonymized WPA peptide calculator sessions.
BPC-157 reconstitution requires mcg-level precision across subcutaneous or intramuscular protocols. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes most commonly used by researchers working with this body protection compound peptide.
BPC-157 is a short protein chain — just 15 amino acids — taken from a protective part of human stomach juice. Researchers call it the Body Protection Compound. It has been studied in animals for over 40 years, almost entirely by one lab in Croatia. No human clinical trials have been published, and no health agency has approved it for any use. What exists is a large body of rodent and dog studies from the Sikiric lab at the University of Zagreb — more than 200 published animal studies over four decades — covering things like tendon healing, gut protection, wound repair, and reduced inflammation. Those animal results are the reason BPC-157 is the most popular healing peptide on the research market today.
BPC-157 is a synthetic 15-amino-acid peptide most often sourced for tendon, ligament, and gut-healing research. It ships as a lyophilized powder reconstituted with bacteriostatic water, and almost all evidence to date comes from animal models.
Proposed mechanisms include up-regulation of the VEGF–nitric-oxide pathway, modulation of growth-hormone-receptor expression in tendon fibroblasts, and stabilization of dopaminergic and serotonergic systems under stress. Pre-clinical work suggests BPC-157 accelerates angiogenesis in injured tissue and protects against NSAID-induced gastrointestinal lesions.
Over 200 published animal studies from the Sikiric lab cover tendon-to-bone healing, transected Achilles repair, inflammatory bowel models, traumatic brain injury, and post-stroke vascular recovery. No Phase 3 trials have been completed in humans; PL 14736 (an oral BPC-157 analog) reached Phase 2 for ulcerative colitis but development was halted. Human evidence remains anecdotal.
BPC-157 has a reported half-life of ~4 hours (subcutaneous, estimated), and the dose intervals researchers model most often fall around twice daily. Short half-life means each dose clears before the next, with minimal buildup between doses. Twice-daily dosing keeps levels closer to a stable working range. It is catalogued under Recovery Peptides on WPA.
4,516 BPC-157 reconstitution calculations have been logged by the WPA community. The most common dose entered is 500mcg (1,602 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (2,693 sessions). The most common dosing frequency is daily (7x/week) (546 logged protocols), followed by once weekly (85).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.